Dr. Korthuis is a Professor of Medicine and Public Health at Oregon Health & Science University where he heads the Addiction Medicine Program. As a general internist, addiction medicine specialist, and clinician scientist, he began his clinical career treating patients living with HIV and has focused on addiction medicine in 2004. He serves as Head of Addiction Medicine at OHSU and directed the OHSU Addiction Medicine Fellowship 2014-2021. His research focuses on developing and integrating addiction treatment and prevention interventions in diverse health care settings. He serves as Co-Principal Investigator of the Western States Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) (UG1DA01581) that tests new treatment strategies for opioid, methamphetamine, and cocaine use disorders. He also serves as Principal Investigator of the Oregon HOPE study to improve engagement in opioid use disorder treatment and harm reduction services in rural Oregon (UH3DA044831), and a peer intervention to improve retention of people who use drugs in clinical trials in rural America (U01TR002631). He also served as site PI and on the data steering committee for the national HIV Research Network, a national clinical registry of more than 30,000 patients living with HIV, 2002-2016. He currently serves as co-investigator on Dr. Stauffer’s trial of psilocybin-assisted therapy for treatment of methamphetamine use disorder. He has authored more than 160 scientific publications and has maintained continuous federal funding for drug research since 2004. Honors include the 2008 Lawrence S. Linn Award for research that improves the lives of people living with HIV and a 2012-2013 Fulbright Scholar award to study integration of HIV and addiction care in Vietnam. Todd serves on the Oregon Psilocybin Services Advisory Board and co-chairs its research committee, where he led development of the Rapid Evidence Review on Psilocybin.